Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • Health Sciences Research Day (MU)
    • 2020 Health Sciences Research Day (MU)
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • Health Sciences Research Day (MU)
    • 2020 Health Sciences Research Day (MU)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Small molecule inhibitors of ATP7A as novel theraphies for cancer

    Vinit, Shanbhag
    Nikita, Gudekar
    Singh, Kamlendra
    Petris, Michael
    View/Open
    [PDF] ShanbhagVinitHSRD2020poster.pdf (674.7Kb)
    Date
    2020
    Format
    Poster
    Metadata
    [+] Show full item record
    Abstract
    Recent studies suggest that trace element copper (Cu) plays a key role in cancer progression. Cu dependent signaling pathways in cancer cells are poorly understood and are being actively investigated. In a recently published PNAS paper, we demonstrated that ATP7A copper transporter promotes breast and lung tumor growth and spread in mice by activating pro cancerous enzyme, lysyl oxidase (LOX). Therefore, we propose that blocking ATP7A using small molecule inhibitors could be a powerful approach in blocking cancer progression. We screened for inhibitors of ATP7A using a structure based virtual screen of ATP7A interacting drug like compounds, resulting in identification of our lead compound, MKV3. We used microscale thermophoresis and standard enzyme activity assays to measure the binding affinity of MKV3 to ATP7A and test the effect of MKV3 on ATP7A dependent LOX and tyrosinase enzymes. In vitro scratch and tumorigenesis assays were performed to test the effect of MKV3 on cancer cell migration and tumor growth. Microscale thermophoresis experiments revealed that MKV3 binds to ATP7A with nanomolar affinity and is a potent inhibitor of ATP7A dependent LOX activity and cell migration of 4T1 breast, LLC and A549 lung cancer cells. Moreover, MKV3 inhibited ATP7A dependent tyrosinase activity in B16 melanoma cells and suppressed B16 tumorigenesis in vivo. In summary, these studies have identified a novel first in class high affinity inhibitor of ATP7A and provide a framework to design MKV3 derivative s with improved therapeutic efficacy in mouse models of cancer. Our findings have the potential for a sustained and powerful impact in cancer therapy.
    URI
    https://hdl.handle.net/10355/79043
    Rights
    OpenAccess.
    This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
    Collections
    • 2020 Health Sciences Research Day (MU)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems